Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
glue · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$37.00
Consensus
$31.75
+89.2% upside
Low
$22.00
Median: $34 · Last Close: $16.78
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$31.75
89.2% upside
High Target
$37
120.5%
Low Target
$22
31.1%
Current Price
$16.78
as of today
Based on analyst price targets, the GLUE stock price prediction for the next 12 months ranges from $22 to $37. The consensus GLUE price forecast of $31.75 implies 89.2% upside from the current price of $16.78.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $15.95 | ↓ 4.94% |
1-day model range: $15.85–$16.05. Peak: $16.05 (-4.94%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GLUE · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-03-18 | Guggenheim | Maintains | Buy→Buy |
| 2026-03-18 | Wells Fargo | Maintains | Overweight→Overweight |
| 2026-01-14 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-01-08 | Guggenheim | Maintains | Buy→Buy |
| 2026-01-08 | Wells Fargo | Maintains | Overweight→Overweight |
| 2025-12-16 | Wells Fargo | Upgrade ↑ | Equal Weight→Overweight |
| 2025-11-07 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2025-03-21 | Wedbush | Maintains | Outperform→Outperform |
| 2025-03-21 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
Wall Street analysts have recently issued updated ratings on Monte Rosa Therapeutics, Inc. (GLUE) stock. Of the recent 30 rating actions, 2 were upgrades and 1 were downgrades. 9 analysts currently cover GLUE.
Analyst Recommendation Trends
GLUE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$44M
↑ 99.8% YoY
Revenue Next Year
$58M
↑ 30.9% YoY
EPS This Year
$-1.66
EPS Next Year
$-1.84
↑ 10.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast GLUE EPS of $-1.66 for the current fiscal year, based on estimates from 5 analysts. The GLUE revenue forecast is $44M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GLUE stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GLUE price target is $31.75 (+89.2% upside), with an analyst consensus of Buy.
The GLUE short-term stock prediction for tomorrow is $15.95 (-4.94%).
Monte Rosa Therapeutics, Inc. trades on NASDAQ under the ticker GLUE. The GLUE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 78% of covering analysts.
Frequently asked questions
GLUE forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month GLUE price target is $31.75, with a high forecast of $37.00 and a low of $22.00. The median price target is shown in the chart above when available. This implies +89.2% potential upside from the current price of $16.78.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.